IP Library › Granted Patent US 10,874,114
Granted Patent B2
US 10,874,114 · App. 15/778,993 · Granted Dec 29, 2020

Supplementation of milk formulas with microvesicles isolated from milk

Inventors: Shimon Reif (Jerusalem, IL); Regina Golan (Maale Michmash, IL)
Assignee: Hadasit Medical Research Services and Development Ltd.
A23C9/1512A23C9/20A23L33/13A23L33/40A61K9/1276A61K31/7105A61P35/00C12N15/111C12N15/113A23C2240/05A23V2002/00A23V2250/18C12N2310/141C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,874,114
App. No.
15/778,993
Granted
Dec 29, 2020
Kind
B2
Abstract

Provided are microvesicles isolated from milk, compositions thereof and uses for the preparation of milk formulas. Further provided are microvesicles, including exosomes and/or fat globules which encapsulate various miRNA molecules and uses thereof, as exemplified by supplementing milk formulas.

Claims (12)

1. A composition comprising infant formula and microvesicles isolated from skim fraction of natural milk, wherein the microvesicles encapsulate or comprise miRNA molecules, wherein the miRNA molecules comprise miR-148a and miR-6073, wherein the microvesicles further encapsulate or comprise biologically active compounds, and wherein the composition substantially does not include cells present in natural milk.

2. The composition of claim 1 , wherein the natural milk is obtained from bovine, goat or human.

3. The composition of claim 1 , wherein the microvesicles comprise exosomes.

4. The composition of claim 1 , wherein the biologically active compounds are selected from nucleic acid molecules, lipids, proteins and peptides.

5. The composition of claim 1 , wherein the infant formula is devoid of animal derived fat other than the fat originating from the microvesicles.

6. The composition of claim 1 , wherein the infant formula does not comprise miRNA molecules other than miRNA molecules comprised within the microvesicles.

7. The composition of claim 1 , wherein the microvesicles are in hydrated or lyophilized form.

8. The composition of claim 1 , wherein the infant formula is formulated for oral administration to infants.

9. The composition of claim 1 , wherein the natural milk is pasteurized.

10. The composition of claim 1 , wherein the natural milk is not pasteurized.

11. A method for enriching an infant formula, the method comprising adding an effective amount of microvesicles isolated from skim fraction of natural milk to the infant formula, thereby obtaining an enriched infant formula composition, wherein the infant formula is devoid of animal derived fat, wherein the microvesicles encapsulate or comprise miRNA molecules, wherein the miRNA molecules comprise miR-148a and miR-6073, wherein the microvesicles further encapsulate or comprise biologically active compounds, and wherein the enriched infant formula composition substantially does not include cells present in natural milk.

12. A method of treating cancer in a subject in need thereof, the method comprising administering a composition comprising milk infant formula and microvesicles isolated from skim fraction of natural milk, wherein the microvesicles encapsulate or comprise miRNA molecules, wherein the miRNA molecules comprise miR-148a and miR-6073, wherein the microvesicles further encapsulate or comprise biologically active compounds, and wherein the composition substantially does not include cells present in natural milk.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2018
From: REIF, SHIMON; GOLAN, REGINA
To: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Reel/Frame 045897/0831 →
Continuity (2)
Provisional Application 62260546 · Nov 29, 2015
Related Publication 20180343882A1 · Dec 6, 2018
Cited By (1)
US 12,409,190